Infraredx Inc. announced the enrollment of 1,000 patients in the Lipid-Rich Plaque (LRP) Study. The LRP Study is a prospective, multi-center clinical trial designed to identify a correlation between lipid-rich plaques detected by Infraredxā€™s TVC Imaging System and the occurrence of a cardiac event within two years.

Biotronik announced that the U.S. Food and Drug Administration (FDA) has approved its DX line of implantable cardioverter defibrillators (ICDs) that can deliver ultra-high energy on the first shock. Also included in the approval response from the FDA is the latest generation of defibrillator devices for patients with complex heart rhythm conditions.

CardiacAssist Inc. announced that it received a Class 3 CE-mark for its Protek DuoĀ veno-venous cannula. The Protek Duo is licensed for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures. It has already been deployed at more than 50 hospitals in the United States since its initial launch in late 2014.

Scientific confirmation has just been published in the American Journal of Cardiovascular Disease that atherosclerosis, the underlying process of heart attacks and strokes, is generally not caused by high cholesterol blood levels. It is rather the result of a structural weakness of the blood vessel walls caused by chronic deficiency of ascorbate (vitamin C).

A new clinical trial is testing the feasibility and efficiency of a doctor in New York City remotely performing long-distance, tele-robotic ultrasound exams over the Internet on patients in Chicago.

Minneapolis Heart Institute Foundation, TMVR, Tendyne, FDA, first implant, U.S.

Minneapolis Heart Institute Foundation (MHIF) physicians are conducting a research study using the first transcatheter mitral valve replacement in the United States at Minneapolis Heart Institute at Abbott Northwestern Hospital.
Subscribe to
Ā© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now